Loading...

Botanix Pharmaceuticals

ASX:BOT
Snowflake Description

Exceptional growth potential with flawless balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
BOT
ASX
A$101M
Market Cap
  1. Home
  2. AU
  3. Pharmaceuticals & Biotech
Company description

Botanix Pharmaceuticals Limited, a clinical stage medical dermatology company, develops therapeutics for the treatment of serious skin diseases in Australia. The last earnings update was 107 days ago. More info.


Add to Portfolio Compare Print
BOT Share Price and Events
7 Day Returns
30%
ASX:BOT
4.2%
AU Biotechs
1.5%
AU Market
1 Year Returns
8.3%
ASX:BOT
15.9%
AU Biotechs
5.1%
AU Market
BOT Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Botanix Pharmaceuticals (BOT) 30% 18.2% 13% 8.3% - -
AU Biotechs 4.2% 5.5% 8.5% 15.9% 94.2% 187.6%
AU Market 1.5% 4% 5.5% 5.1% 24.8% 12%
1 Year Return vs Industry and Market
  • BOT underperformed the Biotechs industry which returned 15.9% over the past year.
  • BOT outperformed the Market in Australia which returned 5.1% over the past year.
Price Volatility
BOT
Industry
5yr Volatility vs Market

Value

 Is Botanix Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Botanix Pharmaceuticals to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Botanix Pharmaceuticals.

ASX:BOT Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 1 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 9.5%
Perpetual Growth Rate 10-Year AU Government Bond Rate 2.3%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for ASX:BOT
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year AU Govt Bond Rate 2.3%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.32
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.318 (1 + (1- 30%) (0%))
1.213
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.21
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.31% + (1.213 * 5.96%)
9.54%

Discounted Cash Flow Calculation for ASX:BOT using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Botanix Pharmaceuticals is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

ASX:BOT DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (AUD, Millions) Source Present Value
Discounted (@ 9.54%)
2019 -11.80 Analyst x1 -10.77
2020 8.90 Analyst x1 7.42
2021 7.30 Analyst x1 5.55
2022 6.34 Est @ -13.14% 4.40
2023 5.80 Est @ -8.51% 3.68
2024 5.50 Est @ -5.26% 3.18
2025 5.33 Est @ -2.99% 2.82
2026 5.26 Est @ -1.4% 2.54
2027 5.24 Est @ -0.29% 2.31
2028 5.27 Est @ 0.49% 2.12
Present value of next 10 years cash flows A$23.24
ASX:BOT DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= A$5.27 × (1 + 2.31%) ÷ (9.54% – 2.31%)
A$74.54
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= A$74.54 ÷ (1 + 9.54%)10
A$29.96
ASX:BOT Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= A$23.24 + A$29.96
A$53.20
Equity Value per Share
(AUD)
= Total value / Shares Outstanding
= A$53.20 / 773.13
A$0.07
ASX:BOT Discount to Share Price
Calculation Result
Value per share (AUD) From above. A$0.07
Current discount Discount to share price of A$0.13
= -1 x (A$0.13 - A$0.07) / A$0.07
-88.9%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Botanix Pharmaceuticals is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Botanix Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Botanix Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ASX:BOT PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in AUD A$-0.02
ASX:BOT Share Price ** ASX (2019-06-14) in AUD A$0.13
Global Biotechs Industry PE Ratio Median Figure of 76 Publicly-Listed Biotechs Companies 20.02x
Australia Market PE Ratio Median Figure of 545 Publicly-Listed Companies 16.04x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Botanix Pharmaceuticals.

ASX:BOT PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:BOT Share Price ÷ EPS (both in AUD)

= 0.13 ÷ -0.02

-6.06x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Botanix Pharmaceuticals is loss making, we can't compare its value to the Global Biotechs industry average.
  • Botanix Pharmaceuticals is loss making, we can't compare the value of its earnings to the Australia market.
Price based on expected Growth
Does Botanix Pharmaceuticals's expected growth come at a high price?
Raw Data
ASX:BOT PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -6.06x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
90.9%per year
Global Biotechs Industry PEG Ratio Median Figure of 54 Publicly-Listed Biotechs Companies 1.23x
Australia Market PEG Ratio Median Figure of 357 Publicly-Listed Companies 1.4x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Botanix Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Botanix Pharmaceuticals's assets?
Raw Data
ASX:BOT PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in AUD A$0.02
ASX:BOT Share Price * ASX (2019-06-14) in AUD A$0.13
Australia Biotechs Industry PB Ratio Median Figure of 43 Publicly-Listed Biotechs Companies 2.6x
Australia Market PB Ratio Median Figure of 1,687 Publicly-Listed Companies 1.65x
ASX:BOT PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:BOT Share Price ÷ Book Value per Share (both in AUD)

= 0.13 ÷ 0.02

8.05x

* Primary Listing of Botanix Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Botanix Pharmaceuticals is overvalued based on assets compared to the AU Biotechs industry average.
X
Value checks
We assess Botanix Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Botanix Pharmaceuticals has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Botanix Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
90.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Botanix Pharmaceuticals expected to grow at an attractive rate?
  • Botanix Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 2.3%.
Growth vs Market Checks
  • Botanix Pharmaceuticals's earnings growth is expected to exceed the Australia market average.
  • Botanix Pharmaceuticals's revenue growth is expected to exceed the Australia market average.
Annual Growth Rates Comparison
Raw Data
ASX:BOT Future Growth Rates Data Sources
Data Point Source Value (per year)
ASX:BOT Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 90.9%
ASX:BOT Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 50.1%
Australia Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 9.8%
Australia Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 8.7%
Australia Market Earnings Growth Rate Market Cap Weighted Average 7.1%
Australia Market Revenue Growth Rate Market Cap Weighted Average 3.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ASX:BOT Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in AUD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ASX:BOT Future Estimates Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-06-30 14 7 7 1
2020-06-30 21 9 10 1
2019-06-30 3 -12 -12 1
ASX:BOT Past Financials Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income *
2018-12-31 5 -10 -13
2018-09-30 3 -10 -12
2018-06-30 2 -10 -11
2018-03-31 2 -8 -8
2017-12-31 2 -7 -6
2017-09-30 1 -6 -5
2017-06-30 -5 -5
2016-12-31 -3
2016-06-30 0 -2

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Botanix Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
  • Botanix Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ASX:BOT Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Botanix Pharmaceuticals Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:BOT Future Estimates Data
Date (Data in AUD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-06-30 0.01 0.01 0.01 1.00
2020-06-30 0.01 0.01 0.01 1.00
2019-06-30 -0.02 -0.02 -0.02 1.00
ASX:BOT Past Financials Data
Date (Data in AUD Millions) EPS *
2018-12-31 -0.02
2018-09-30 -0.02
2018-06-30 -0.02
2018-03-31 -0.02
2017-12-31 -0.01
2017-09-30 -0.01
2017-06-30 -0.01
2016-12-31 -0.01
2016-06-30 -0.01

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Botanix Pharmaceuticals is expected to make outstanding use of shareholders’ funds in the future (Return on Equity greater than 40%).
X
Future performance checks
We assess Botanix Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Australia market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Australia market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Botanix Pharmaceuticals has a total score of 6/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Botanix Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Botanix Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Botanix Pharmaceuticals does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Botanix Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Botanix Pharmaceuticals's 1-year growth to the Global Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Botanix Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Botanix Pharmaceuticals Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:BOT Past Revenue, Cash Flow and Net Income Data
Date (Data in AUD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 4.67 -12.80 2.09
2018-09-30 3.22 -11.91 1.96
2018-06-30 1.78 -11.01 1.84
2018-03-31 1.78 -8.47 1.73
2017-12-31 1.78 -5.92 1.63
2017-09-30 0.89 -5.35 1.35
2017-06-30 -4.77 1.07
2016-12-31 -2.95 0.50
2016-06-30 -1.86 0.29

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Botanix Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Botanix Pharmaceuticals has efficiently used its assets last year compared to the Global Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Botanix Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Botanix Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Botanix Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Botanix Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Botanix Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Botanix Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Botanix Pharmaceuticals has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Botanix Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Botanix Pharmaceuticals has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Botanix Pharmaceuticals Company Filings, last reported 5 months ago.

ASX:BOT Past Debt and Equity Data
Date (Data in AUD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 12.24 0.00 13.53
2018-09-30 12.24 0.00 13.53
2018-06-30 16.28 0.00 17.26
2018-03-31 16.28 0.00 17.26
2017-12-31 3.29 0.00 2.25
2017-09-30 3.29 0.00 2.25
2017-06-30 5.44 0.00 5.72
2016-12-31 2.02 0.00 2.37
2016-06-30 3.18 0.00 3.65
  • Botanix Pharmaceuticals has no debt.
  • Botanix Pharmaceuticals has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Botanix Pharmaceuticals has sufficient cash runway for 1.3 years based on current free cash flow.
  • Botanix Pharmaceuticals has sufficient cash runway for 1.2 years if free cash flow continues to grow at historical rates of 62.1% each year.
X
Financial health checks
We assess Botanix Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Botanix Pharmaceuticals has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Botanix Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Botanix Pharmaceuticals dividends.
If you bought A$2,000 of Botanix Pharmaceuticals shares you are expected to receive A$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Botanix Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Botanix Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ASX:BOT Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 19 Stocks 2.4%
Australia Market Average Dividend Yield Market Cap Weighted Average of 415 Stocks 4.1%
Australia Minimum Threshold Dividend Yield 10th Percentile 1.6%
Australia Bottom 25% Dividend Yield 25th Percentile 2.7%
Australia Top 25% Dividend Yield 75th Percentile 5.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

ASX:BOT Future Dividends Estimate Data
Date (Data in A$) Dividend per Share (annual) Avg. No. Analysts
2021-06-30
2020-06-30
2019-06-30

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Botanix Pharmaceuticals has not reported any payouts.
  • Unable to verify if Botanix Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Botanix Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Botanix Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Botanix Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.6%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Botanix Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Botanix Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Botanix Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
  • Botanix Pharmaceuticals has no CEO, or we have no data on them.
Management Team Tenure

Average tenure of the Botanix Pharmaceuticals management team in years:

1.6
Average Tenure
  • The average tenure for the Botanix Pharmaceuticals management team is less than 2 years, this suggests a new team.
Management Team

Matt Callahan

TITLE
Founder & Executive Director
COMPENSATION
A$164K
AGE
45

Michael Thurn

TITLE
COO & Executive Director
COMPENSATION
A$384K
TENURE
2.3 yrs

Bill Bosch

TITLE
Chief Scientific Officer & Executive Director
COMPENSATION
A$203K

Vince Ippolito

TITLE
President
AGE
59
TENURE
0.1 yrs

Stephane Levy

TITLE
Chief Medical Officer
TENURE
0.9 yrs

Simon Robertson

TITLE
Company Secretary
TENURE
2.3 yrs
Board of Directors Tenure

Average tenure and age of the Botanix Pharmaceuticals board of directors in years:

2.9
Average Tenure
48
Average Age
  • The average tenure for the Botanix Pharmaceuticals board of directors is less than 3 years, this suggests a new board.
Board of Directors

Stewart Washer

TITLE
Interim Non-Executive Chairman
AGE
48
TENURE
0.3 yrs

Matt Callahan

TITLE
Founder & Executive Director
COMPENSATION
A$164K
AGE
45
TENURE
2.9 yrs

Michael Thurn

TITLE
COO & Executive Director
COMPENSATION
A$384K
TENURE
0.3 yrs

Bill Bosch

TITLE
Chief Scientific Officer & Executive Director
COMPENSATION
A$203K
TENURE
2.9 yrs

Rob Towner

TITLE
Non-Executive Director
COMPENSATION
A$97K
AGE
49
TENURE
5.4 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (A$) Value (A$)
X
Management checks
We assess Botanix Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Botanix Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Botanix Pharmaceuticals Limited's (ASX:BOT) Profit Outlook

Botanix Pharmaceuticals Limited's (ASX:BOT): Botanix Pharmaceuticals Limited, a clinical stage medical dermatology company, develops therapeutics for the treatment of serious skin diseases in Australia. … Check out our latest analysis for Botanix Pharmaceuticals Expectation from Biotechs analysts is BOT is on the verge of breakeven. … Working backwards from analyst estimates, it turns out that they expect the company to grow 91% year-on-year, on average, which is extremely buoyant.

Simply Wall St -

Do Insiders Own Lots Of Shares In Botanix Pharmaceuticals Limited (ASX:BOT)?

If you want to know who really controls Botanix Pharmaceuticals Limited (ASX:BOT), then you'll have to look at the makeup of its share registry. … Botanix Pharmaceuticals is not a large company by global standards. … View our latest analysis for Botanix Pharmaceuticals

Simply Wall St -

When Can We Expect A Profit From Botanix Pharmaceuticals Limited (ASX:BOT)?

Botanix Pharmaceuticals Limited's (ASX:BOT):. … Botanix Pharmaceuticals Limited, a clinical stage medical dermatology company, develops therapeutics for the treatment of serious skin diseases in Australia. … Check out our latest analysis for Botanix Pharmaceuticals

Simply Wall St -

Could The Botanix Pharmaceuticals Limited (ASX:BOT) Ownership Structure Tell Us Something Useful?

If you want to know who really controls Botanix Pharmaceuticals Limited (ASX:BOT), then you'll have to look at the makeup of its share registry. … Botanix Pharmaceuticals is not a large company by global standards. … institutional investors have not yet purchased much of the company.

Simply Wall St -

When Will Botanix Pharmaceuticals Limited (ASX:BOT) Become Profitable?

Botanix Pharmaceuticals Limited, a clinical stage medical dermatology company, develops therapeutics for the treatment of serious skin diseases in Australia. … The AU$58m market-cap company announced a latest loss of -AU$11.0m on 30 June 2018 for its most recent financial year result? … Check out our latest analysis for Botanix Pharmaceuticals

Simply Wall St -

What does Botanix Pharmaceuticals Limited's (ASX:BOT) Balance Sheet Tell Us About Its Future?

However, it also faces higher cost of capital given interest cost is generally lower than equity. … Is BOT growing fast enough to value financial flexibility over lower cost of capital … Debt capital generally has lower cost of capital compared to equity funding.

Simply Wall St -

Should You Be Concerned About Botanix Pharmaceuticals Limited's (ASX:BOT) Shareholders?

This level of insider ownership has been found to have a negative impact on companies with consistently low PE ratios (underperformers), while it has been positive in the case of high PE ratio firms (outperformers). … Private Company Ownership Another important group of owners for potential investors in BOT are private companies that hold a stake of 6.25% in BOT. … Thus, potential investors should look into these business relations and check how it can impact long-term shareholder returns.Next Steps: Institutional ownership level and composition in BOT is not high nor active enough to significantly impact its investment thesis.

Simply Wall St -

Botanix Pharmaceuticals Limited (ASX:BOT): Does The -100.59% Earnings Drop Reflect A Longer Term Trend?

Check out our latest analysis for Botanix Pharmaceuticals Was BOT's weak performance lately a part of a long-term decline? … ASX:BOT Income Statement Mar 13th 18 We can further evaluate Botanix Pharmaceuticals's loss by looking at what the industry has been experiencing over the past few years. … Each year, for the past five years Botanix Pharmaceuticals's top-line more than doubled on average, indicating that the business is in a high-growth phase with expenses racing ahead revenues, leading to annual losses.

Simply Wall St -

ASX Healthcare Industry: A Deep Dive Into Botanix Pharmaceuticals Limited (ASX:BOT)

In this article, I’ll take you through the sector growth expectations, as well as evaluate whether Botanix Pharmaceuticals is lagging or leading its competitors in the industry. … Botanix Pharmaceuticals lags the pack with its lower growth rate of 7.15% over the past year, which indicates the company will be growing at a slower pace than its biotech peers. … If your initial investment thesis is around the growth prospects of Botanix Pharmaceuticals, there are other biotech companies that have delivered higher growth, and perhaps trading at a discount to the industry average.

Simply Wall St -

Who Are The Major Shareholders In Botanix Pharmaceuticals Limited (ASX:BOT)?

Check out our latest analysis for Botanix Pharmaceuticals ASX:BOT Ownership Summary Nov 1st 17 Institutional Ownership Due to the big order sizes of institutional investors, a company's shares can experience large, one-sided momentum, driven by high volume of shares removed from, or injected into, the market. … This size of ownership gives retail investors collective power in deciding on major policy decisions such as executive compensation, appointment of directors and acquisitions of businesses. … This level of ownership gives retail investors the power to sway key policy decisions such as board composition, executive compensation, and potential acquisitions.

Simply Wall St -

Company Info

Description

Botanix Pharmaceuticals Limited, a clinical stage medical dermatology company, develops therapeutics for the treatment of serious skin diseases in Australia. The company offers BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers; BTX 1308, a transdermal gel formulation for the treatment of plaque psoriasis; BTX 1204, a transdermal gel formation for the treatment of atopic dermatitis; and BTX 1701, a novel product for mild acne. Botanix Pharmaceuticals Limited is based in Perth, Australia.

Details
Name: Botanix Pharmaceuticals Limited
BOT
Exchange: ASX
Founded:
A$100,506,666
773,128,204
Website: http://www.botanixpharma.com
Address: Botanix Pharmaceuticals Limited
50 Angove Street North,
Perth,
Western Australia, 6006,
Australia
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX BOT Ordinary Shares Australian Securities Exchange AU AUD 05. Jul 2016
CHIA BOT Ordinary Shares Chi-X Australia AU AUD 05. Jul 2016
Number of employees
Current staff
Staff numbers
10
Botanix Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/06/15 10:38
End of day share price update: 2019/06/14 00:00
Last estimates confirmation: 2018/11/21
Last earnings filing: 2019/02/28
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.